Halozyme Therapeutics (NASDAQ:HALO) executives highlighted the company’s royalty-driven growth outlook and expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences Conference, pointing to strong momentum from key partnered products, new collaboration activity, and recent acquisitions designed to broaden its addressable market beyond ENHANZE. 2026 revenue and profitability framework CEO Helen Torley reiterated […]